

Title (en)
IL-8 RECEPTOR ANTAGONISTS

Title (de)
IL-8-REZEPTOR-ANTAGONISTEN

Title (fr)
ANTAGONISTES DES RECEPTEURS DE L'IL-8

Publication
EP 1185261 A4 20040225 (EN)

Application
EP 00942843 A 20000615

Priority
• US 0016499 W 20000615
• US 13967599 P 19990616

Abstract (en)
[origin: WO0076495A1] This invention provides for a method of treating a chemokine mediated disease, wherein the chemokine is one which binds to an IL-8 alpha or beta receptor and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In particular the chemokine is IL-8.

IPC 1-7
A61K 31/17; **A61K 31/277**

IPC 8 full level
A61K 31/17 (2006.01); **A61K 31/18** (2006.01); **C07D 317/58** (2006.01); **A61K 31/235** (2006.01); **A61K 31/27** (2006.01); **A61K 31/275** (2006.01); **A61K 31/36** (2006.01); **A61K 31/381** (2006.01); **A61K 31/426** (2006.01); **A61K 31/47** (2006.01); **A61P 1/02** (2006.01); **A61P 7/00** (2006.01); **A61P 9/10** (2006.01); **A61P 19/10** (2006.01); **A61P 31/16** (2006.01); **A61P 31/20** (2006.01); **A61P 33/06** (2006.01); **A61P 43/00** (2006.01); **C07D 215/36** (2006.01); **C07D 277/20** (2006.01); **C07D 277/52** (2006.01); **C07D 333/34** (2006.01); **C07D 333/36** (2006.01)

CPC (source: EP KR)
A61K 31/17 (2013.01 - EP); **A61K 31/27** (2013.01 - KR); **A61P 1/02** (2018.01 - EP); **A61P 7/00** (2018.01 - EP); **A61P 9/10** (2018.01 - EP); **A61P 19/10** (2018.01 - EP); **A61P 31/16** (2018.01 - EP); **A61P 31/20** (2018.01 - EP); **A61P 33/06** (2018.01 - EP); **A61P 43/00** (2018.01 - EP); **Y02A 50/30** (2018.01 - EP)

Citation (search report)
• [X] WO 9729743 A1 19970821 - SMITHKLINE BEECHAM CORP [US], et al
• [X] WO 9625157 A1 19960822 - SMITHKLINE BEECHAM CORP [US], et al
• [PX] WO 0016768 A1 20000330 - SMITHKLINE BEECHAM CORP [US], et al
• [X] "Interleukin-8 receptor antagonists", EXPERT OPINION ON THERAPEUTIC PATENTS 1998 UNITED KINGDOM, vol. 8, no. 4, 1998, pages 471 - 473, XP002265289, ISSN: 1354-3776
• [X] PONATH P D: "CHEMOKINE RECEPTOR ANTAGONISTS: NOVEL THERAPEUTICS FOR IMFLAMMATIONAND AIDS", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 7, no. 1, January 1998 (1998-01-01), pages 1 - 18, XP000882089, ISSN: 1354-3784
• [A] HOWARD O M Z ET AL: "CHEMOKINES: PROGRESS TOWARD IDENTIFYING MOLECULAR TARGETS FOR THERAPEUTIC AGENTS", TRENDS IN BIOTECHNOLOGY, ELSEVIER, AMSTERDAM,, GB, vol. 14, February 1996 (1996-02-01), pages 46 - 51, XP002919059, ISSN: 0167-7799
• See also references of WO 0076495A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 0076495 A1 20001221; AR 030391 A1 20030820; AU 5741300 A 20010102; AU 766083 B2 20031009; BR 0010802 A 20020219; CA 2377341 A1 20001221; CN 1355697 A 20020626; CO 5200760 A1 20020927; CZ 20014471 A3 20020814; EP 1185261 A1 20020313; EP 1185261 A4 20040225; HK 1044483 A1 20021025; HU P0201571 A2 20020828; HU P0201571 A3 20021128; IL 145761 A0 20020725; JP 2003501459 A 20030114; KR 20020010709 A 20020204; MX PA01013004 A 20020730; NO 20016053 D0 20011211; NO 20016053 L 20011211; NZ 514695 A 20040528; PL 352232 A1 20030811; TR 200103680 T2 20020722; ZA 200109479 B 20021118

DOCDB simple family (application)
US 0016499 W 20000615; AR P000102923 A 20000614; AU 5741300 A 20000615; BR 0010802 A 20000615; CA 2377341 A 20000615; CN 00809045 A 20000615; CO 00043844 A 20000613; CZ 20014471 A 20000615; EP 00942843 A 20000615; HK 02106188 A 20020822; HU P0201571 A 20000615; IL 14576100 A 20000615; JP 2001502828 A 20000615; KR 20017016142 A 20011215; MX PA01013004 A 20000615; NO 20016053 A 20011211; NZ 51469500 A 20000615; PL 35223200 A 20000615; TR 200103680 T 20000615; ZA 200109479 A 20011116